Background and Objective: BRAF mutations were studied in various populations for prostate carcinoma (PC); however, mutations in BRAF gene are unusual compared to KRAS. Oncogenic activating of BRAF mutations were studied lately in almost 0%-10% of prostate cancer cases. Methods: In this retrospective study, we gathered 100 formalin-fixed ...

aim : we aimed to explore the frequency of braf v600e mutation in iranian patients with colorectal cancer (crc) as well as its association with clinic pathological characteristic of patients.   background : crc is the third leading cause of cancer related death. there is a growing body of data showing the association of braf v600e mutation with malignant transformation and clinical outcome of d...

background kras and braf gene mutations are considered as key events in carcinogenesis progression of colorectal cancer. given the importance of these gene mutations evaluations, especially in metastatic patients, in terms of determination of therapeutic strategies, we studied the prevalence of kras and braf mutations in tabriz city.   materials and methods deoxyribonucleic acid (dna) extracted...

knowledge about the clinical significance of v-raf murine sarcoma viral oncogene homolog b1 ( braf ) mutations in colorectal cancer (crc) is growing. braf encodes a protein kinase involved with intracellular signaling and cell division. the gene product is a downstream effector of kirsten ras 1( kras ) within the ras/raf/mapk cellular signaling pathway. evidence suggests that braf mutations, li...

Background The development of BRAF/MEK inhibitors in patients with metastatic melanoma harboring BRAF mutations has garnered attention for liquid biopsy to detect cell-free DNA (cfDNA) using droplet digital PCR (ddPCR) or next-generation sequencing methods. Objective To investigate gene tumor and cfDNA collected from 43 evaluate their potential as biomarkers. Methods ddPCR CAncer Personalized P...

Mutations in the BRAF oncogene occur in the majority of melanomas, leading to the activation of the mitogen-activated protein kinase pathway and the transcription of downstream effectors. As BRAF and its effectors could be good melanoma therapy targets, defining the repertoire of genes that are differentially regulated because of BRAF mutational activation is an important objective. Towards thi...

Colorectal cancer patients with the BRAF(p.V600E) mutation have poor prognosis in metastatic setting. Personalized treatment options and companion diagnostics are needed to better treat these patients. Previously, we developed a 58-gene signature to characterize the distinct gene expression pattern of BRAF-mutation-like subtype (accuracy 91.1%). Further experiments repurposed drug Vinorelbine a...

Point mutation of the BRAF gene is a genetic event that occurs in a subset of lung adenocarcinoma cases. For example, BRAF V600E is a driver mutation that can be effectively targeted using selective BRAF and/or MEK inhibitors. The present study hypothesized that an increase in BRAF copy number may be correlated with certain clinicopathological features of lung adenocarcinoma in Japanese patient...